Loomis, Sayles & Company’s Globus Medical GMED Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-202,847
| Closed | -$14.8M | – | 755 |
|
|
2025
Q1 | $14.8M | Buy |
+202,847
| New | +$16.8M | 0.02% | 288 |
|
|
2023
Q1 | – | Sell |
-511,496
| Closed | -$38M | – | 994 |
|
|
2022
Q4 | $38M | Buy |
511,496
+3,407
| +0.7% | +$232K | 0.08% | 138 |
|
|
2022
Q3 | $30.3M | Sell |
508,089
-5,447
| -1% | -$328K | 0.06% | 157 |
|
|
2022
Q2 | $28.8M | Sell |
513,536
-3,577
| -0.7% | -$235K | 0.05% | 178 |
|
|
2022
Q1 | $38.2M | Buy |
517,113
+18,000
| +4% | +$1.25M | 0.05% | 179 |
|
|
2021
Q4 | $36M | Sell |
499,113
-5,061
| -1% | -$367K | 0.04% | 229 |
|
|
2021
Q3 | $38.6M | Buy |
504,174
+14,036
| +3% | +$1.13M | 0.05% | 207 |
|
|
2021
Q2 | $38M | Buy |
490,138
+19,285
| +4% | +$1.37M | 0.05% | 217 |
|
|
2021
Q1 | $29M | Buy |
470,853
+948
| +0.2% | +$60K | 0.04% | 238 |
|
|
2020
Q4 | $30.6M | Buy |
469,905
+116,812
| +33% | +$6.72M | 0.04% | 201 |
|
|
2020
Q3 | $17.5M | Sell |
353,093
-3,712
| -1% | -$191K | 0.03% | 250 |
|
|
2020
Q2 | $17M | Buy |
356,805
+27,710
| +8% | +$1.34M | 0.03% | 246 |
|
|
2020
Q1 | $14M | Buy |
329,095
+64,597
| +24% | +$3.19M | 0.03% | 240 |
|
|
2019
Q4 | $15.6M | Sell |
264,498
-20,044
| -7% | -$1.09M | 0.03% | 268 |
|
|
2019
Q3 | $14.5M | Buy |
284,542
+87,445
| +44% | +$4.16M | 0.03% | 270 |
|
|
2019
Q2 | $8.34M | Sell |
197,097
-11,859
| -6% | -$515K | 0.02% | 370 |
|
|
2019
Q1 | $10.3M | Buy |
208,956
+38,050
| +22% | +$1.72M | 0.02% | 342 |
|
|
2018
Q4 | $7.4M | Buy |
170,906
+170,724
| +93,804% | +$8.52M | 0.02% | 368 |
|
|
2018
Q3 | $10K | Hold |
182
| – | – | ﹤0.01% | 804 |
|
|
2018
Q2 | $9K | Sell |
182
-24
| -12% | -$1.25K | ﹤0.01% | 803 |
|
|
2018
Q1 | $10K | Sell |
206
-22
| -10% | -$1.03K | ﹤0.01% | 805 |
|
|
2017
Q4 | $9K | Sell |
228
-602
| -73% | -$21.1K | ﹤0.01% | 784 |
|
|
2017
Q3 | $25K | Sell |
830
-369
| -31% | -$11.3K | ﹤0.01% | 726 |
|
|
2017
Q2 | $40K | Buy |
1,199
+79
| +7% | +$2.48K | ﹤0.01% | 634 |
|
|
2017
Q1 | $33K | Buy |
1,120
+860
| +331% | +$23.5K | ﹤0.01% | 682 |
|
|
2016
Q4 | $6K | Hold |
260
| – | – | ﹤0.01% | 889 |
|
|
2016
Q3 | $6K | Sell |
260
-676,382
| -100% | -$15.9M | ﹤0.01% | 848 |
|
|
2016
Q2 | $16.1M | Sell |
676,642
-16,390
| -2% | -$393K | 0.04% | 329 |
|
|
2016
Q1 | $16.5M | Buy |
+693,032
| New | +$16.9M | 0.05% | 326 |
|
|
2014
Q3 | – | Sell |
-984,669
| Closed | -$23.6M | – | 730 |
|
|
2014
Q2 | $23.6M | Sell |
984,669
-38,625
| -4% | -$932K | 0.07% | 289 |
|
|
2014
Q1 | $27.2M | Buy |
1,023,294
+121,249
| +13% | +$2.88M | 0.08% | 245 |
|
|
2013
Q4 | $18.2M | Buy |
902,045
+901,379
| +135,342% | +$16.7M | 0.05% | 387 |
|
|
2013
Q3 | $12K | Buy |
+666
| New | +$11.5K | ﹤0.01% | 732 |
|
Other funds holding GMED
BAM
SC
HRCM
GCM
Loomis, Sayles & Company's GMED Position: Q2 2025 in Review
Loomis, Sayles & Company sold out of Globus Medical (GMED) in Q2 2025, closing a stake of 202,847 shares — an estimated $14.8M sold.
Loomis, Sayles & Company first reported a position in GMED in Q3 2013 and held it in 33 quarters. The position peaked at $38.6M in Q3 2021. 480 funds tracked by Wall St. Rank hold GMED as of Q2 2025.
- Loomis, Sayles & Company reported no remaining Globus Medical position as of Q2 2025 after selling out during the quarter.
- Loomis, Sayles & Company sold 202,847 Globus Medical shares in Q2 2025, an estimated $14.8M.
- Loomis, Sayles & Company first reported a position in Globus Medical in Q3 2013 and held it in 33 quarters.
- Loomis, Sayles & Company's Globus Medical position peaked at $38.6M in Q3 2021.
- 480 funds tracked by Wall St. Rank held Globus Medical as of Q2 2025.
Based on Loomis, Sayles & Company's 13F filing for Q2 2025, filed 13 Aug 2025.